BPC-157 + TB-500
Two-peptide research blend · Research-grade reference material
Identity
- Molecular formula
- N/A — 2-component combination preparation (BPC-157 10mg + TB-500 10mg per vial)
- Molecular weight
- —
- CAS number
- —
Research Background
BPC-157 is a synthetic 15-amino-acid peptide based on a sequence from human gastric juice, studied primarily for angiogenesis, new blood vessel formation into damaged tissue, via VEGFR2 activation.
TB-500 (Thymosin Beta-4) is a naturally occurring 43-amino-acid actin-sequestering protein, studied for its role in cell migration, cells physically moving toward and through damaged tissue during repair.
Lab-tested research material
BPC-157 + TB-500
From $69.00 · HPLC purity BPC-157 99.53% · TB-500 99.16% · Batch See individual COAs COA
View current batch and sizes →Mechanism
The pairing rationale is mechanistic: BPC-157 is studied for opening new vascular supply routes into an injury site, while TB-500 is studied for enabling the cell migration that repair depends on once that supply exists. Two distinct repair pathways, new blood vessels and cell movement, that could plausibly be complementary.
This combination product bundles two individually documented peptides. BPC-157 has been investigated in published preclinical research since the early 1990s across tissue-repair, gastrointestinal, vascular and neurological models, and is frequently characterized as notably stable in aqueous and acidic conditions. TB-500 (thymosin β4's active region) has been studied in preclinical tissue-repair research across wound-healing, cardiovascular, corneal and musculoskeletal models since the late 1990s–2000s. Findings below derive from animal and cell-culture systems for each compound studied individually; they are not established effects in humans.
BPC-157 — Angiogenesis via VEGFR2 signaling. Endothelial responses reported through the VEGFR2–Akt–eNOS axis (Hsieh et al.).
BPC-157 — Nitric oxide (NO) system modulation. Interaction with the Src–caveolin-1–eNOS pathway; magnitude and direction remain under active debate in the 2025 literature.
BPC-157 — Growth-hormone receptor (GHR) upregulation. Increased GHR expression and downstream JAK2 signaling in tendon fibroblast cultures.
BPC-157 — FAK–paxillin and ERK1/2 signaling. Implicated in cell-migration and tissue-repair models.
BPC-157 — Anti-inflammatory modulation. Reduced pro-inflammatory cytokines in injury models.
TB-500 — Actin sequestration (foundational). High-affinity 1:1 binding to monomeric G-actin (reported Kd ≈ 0.5–0.7 µM), influencing polymerization and cell migration.
TB-500 — Cell migration & re-epithelialization. Promotes keratinocyte and fibroblast migration in preclinical wound models.
TB-500 — Angiogenesis. Endothelial migration and tubule formation; the LKKTET motif is implicated (mutation reduces activity).
TB-500 — Anti-inflammatory modulation. NF-κB-associated modulation of inflammatory signaling in injury models.
Proposed pathways investigated in preclinical (animal / in-vitro) models, for each constituent studied individually. Schematic only; not a claim of established human effect for this combination.
State of the Evidence
No study has tested this combination directly. Each component’s research record stands entirely on its own; BPC-157’s angiogenesis findings and TB-500’s cell-migration findings come from separate studies using each peptide in isolation. The complementary logic above is a hypothesis based on the two individual mechanisms, not a demonstrated combination effect. The important next step for this pairing is a controlled study testing the combination directly, which does not yet exist.
BPC-157
What the Literature Supports — and What It Doesn’t
The preclinical mechanistic literature is substantial and, in several pathways, coherent across laboratories. Human data remains very limited. Honest characterization matters for a research reference.
Evidence at a glance
The overwhelming majority of data is from animal and cell-culture models, not humans.
Human data is limited to small pilot studies, primarily tolerability rather than efficacy, without independent replication.
No large, controlled human efficacy trials have been published.
Appropriate characterization: a peptide with an extensive preclinical research literature and coherent proposed mechanisms, awaiting rigorous human study. Statements that BPC-157 “heals” or “treats” any condition in humans are not supported by current published evidence.
Regulatory & status notes
Selected references
- 1. Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025. (PMC12313605)
- 2. Józwiak M, et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review. Pharmaceuticals. 2025;18:185.
- 3. Hsieh MJ, et al. BPC-157 enhances angiogenesis via the VEGFR2–Akt–eNOS pathway (preclinical). PubMed 27847966.
- 4. Cushman CJ, et al. Local and Systemic Peptide Therapies for Soft Tissue Injury and Wound Healing. 2024. (PMC11426299)
TB-500
What the Literature Supports — and What It Doesn’t
The actin-sequestration mechanism and preclinical wound-healing / angiogenesis findings are documented across multiple laboratories. A key nuance: most primary evidence concerns full-length thymosin β4, not the TB-500 fragment as sold by reagent vendors.
Evidence at a glance
Most robust evidence concerns full-length Tβ4; sequence and quality vary between vendor sources of “TB-500.”
The legitimate clinical path is RGN-259 (a Tβ4-based ophthalmic candidate) — as of 2026 at phase 3, with no approved marketed product.
No human randomized controlled trial supports systemic use for musculoskeletal injury; no regulatory approvals for therapeutic use.
Appropriate characterization: a well-studied actin-regulating peptide with substantial preclinical tissue-repair literature and one active pharmaceutical program (ophthalmology), awaiting approved clinical outcomes.
Regulatory & status notes
Selected references
- 1. Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review. Applied Sciences (MDPI). 2026;16(12):6202.
- 2. Goldstein AL, Kleinman HK. Thymosin β4 in tissue repair and wound healing (foundational literature).
- 3. Bock-Marquette I, et al. Thymosin β4 mediates cardioprotective effects (porcine MI model).
- 4. Malinda KM, et al. Thymosin β4 accelerates wound healing. J Invest Dermatol. 1999.
Safety Information
Research-use compound with limited human data on either component individually, and none on the combination specifically. Evidence strength varies — see the individual Registry entries for BPC-157 and TB-500.
No established clinical contraindications. This is an investigational combination with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician. For research and educational purposes only, not for human or veterinary use.
Related Compounds
For research and educational purposes only. Not for human or veterinary use.